


## HPTN IN THE NEWS

### New WHO Guidelines Recommend Universal Antiretroviral Treatment, PrEP for Those at Substantial Risk

This early-release guideline makes two key recommendations available that were developed during the revision process in 2015. The recommendations in this guideline will form part of the revised consolidated guidelines on the use of ARV drugs for treating and preventing HIV infection to be published by WHO in 2016. Multiple HPTN studies ([046](#), [052](#), [067](#), and [071](#)) are discussed in the guidelines. [Read more.](#)



## SPOTLIGHT ON THE COMMUNITY

### HPTN/MTN Community Writing Workshop



The HPTN and MTN Community Writing Group hosted 87 community

## Upcoming Events

### [HPTN Regional Meeting](#)

Oct. 24-25  
Cape Town, South Africa

### [APHA](#)

Oct.31-Nov. 4  
Chicago, Ill.

### [ICASA](#)

Nov. 8-13  
Hammamet, Tunisia

### [International Conference on HIV/AIDS, STDs & STIs](#)

Nov. 30-Dec. 2  
Atlanta, Ga.

### [National HIV Prevention Conference](#)

Dec. 6-9  
Atlanta, Ga.

### [CROI](#)

Feb. 22-25  
Boston, Mass.

## Study Updates

### [HVTN 703/HPTN 081](#)

HVTN 703/HPTN 081, also known as AMP (Antibody Mediated Prevention), is a Phase 2b clinical trial to evaluate the safety, efficacy and immunogenicity of VRC01, a broadly neutralizing monoclonal antibody (bNab) in reducing acquisition of HIV-1 infection

360's Durham office for a weeklong writing workshop to enhance their manuscript writing skills. The workshop is expecting to produce 12 new manuscripts! Musonda Simwanga, who works on HPTN 071 in Zambia said the workshop taught him a lot. "I really learned that we need to tell the community engagement story to the rest of the world," he said. "And what better place to tell it (through our writing) because we are the frontline people in the community." [View photos.](#)

## SPOTLIGHT ON NETWORK MEMBERS

### Conversations With the HPTN



#### How did you first become involved with the HPTN?

When I was at the Division of AIDS/NIAID (1988-1994), I co-wrote the RFA that resulted in the domestic and international HIVNET grants. Coming into academia, I was recused from working with HIVNET for several years to avoid conflict of interest. But when Ward Cates and Steve Self started to mobilize for a response to the new HPTN RFA, as a partial successor to HIVNET, they invited me to an organizational meeting in a scenic Chicago O'Hare airport conference room (no windows at all) and I was most pleased to accept this invitation! [Read more.](#)

## HOT OFF THE PRESS

Tieu HV, Liu TY, Hussen S, Connor M, Wang L, Buchbinder S, Wilton L, Gorbach P, Mayer K, Griffith S, Kelly C, Elharrar V, Phillips G, Cummings V, Koblin B, Latkin C, HPTN. 2015. [Sexual Networks and HIV Risk among Black Men Who Have Sex with Men in 6 U.S. Cities.](#) PLoS One 10:e0134085.

Chen I, Clarke W, Ou SS, Marzinke MA, Breaud A, Emel LM, Wang J, Hughes JP, Richardson P, Haley DF, Lucas J, Rompalo A, Justman JE, Hodder SL, Eshleman SH. 2015. [Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064.](#) PLoS One 10:e0140074.

Magidson JF, Li X, Mimiaga MJ, Moore AT, Srithanaviboonchai K, Friedman RK, Limbada M, Hughes JP, Cummings V, Gaydos CA, Elharrar V, Celentano D, Mayer KH, Safren SA. 2015. [Antiretroviral Medication Adherence and Amplified HIV Transmission Risk Among Sexually Active HIV-Infected Individuals in Three Diverse International Settings.](#) AIDS and Behavior.

Hendrix CW, Andrade A, Bumpus NN, Kashuba A, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I, Radebaugh C, Prince H,

The study is expected to begin in November. [Read more.](#)

### HPTN 082

HPTN 082 is a prospective study that will assess PrEP acceptance, adherence, acceptability, and continuation among a cohort of 400 HIV negative women ages 16 to 25 at three sites in southern Africa. The study is expected to begin in 2016. [Read more.](#)

### HPTN 083

HPTN 083 is a Phase 2B/3 double-blind randomized study that will assess the efficacy of quarterly injections of cabotegravir (CAB LA) for PrEP among 4,500 HIV-uninfected MSM and transgender women who have sex with men by comparing it with daily oral PrEP (FTC-TDF). The study is expected to begin in 2016 at research sites located in the Americas and Asia. [Read more.](#)

## Awareness Days



### Follow us on social media



Bakshi RP, Wang R, Richardson P, Shieh E, McKinstry L, Li X, Donnell D, ElHarrar V, Mayer KH, Patterson K. 2015. [Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine after Directly Observed Dosing in Healthy Volunteers to establish Adherence Benchmarks \(HPTN 066\)](#). AIDS Research and Human Retroviruses.

## NEWSLETTER CHANGES

Based on feedback from the recent communications survey, we are now distributing the newsletter each month to ensure the Network stays well-informed and involved.

What would you like to see from our newsletters? Please e-mail us with your thoughts and ideas at [news@hptn.org](mailto:news@hptn.org).

Share this email:



[Manage](#) your preferences | [Opt out](#) using TrueRemove™

Got this as a forward? [Sign up](#) to receive our future emails.

View this email [online](#).

359 Blackwell Street, Suite 200  
Durham, NC | 27701 US

This email was sent to .

*To continue receiving our emails, add us to your address book.*

